PURPOSE:

 

The aim of this work was to review new and clinical practice PET radiopharmaceuticals for prostate cancer imaging.

 

METHODS:

 

PET radiopharmaceuticals were reviewed on the main databases. Availability, dosimetry, accuracy and limitations were considered.

 

RESULTS:

 

The following radioisotopes with respective physical half-life and mean positron energy were found: (18)F (109,7 min, 249,8 keV), (89)Zr (78,4 hs, 395,5 keV), (11)C (20,4 min, 385,7 keV) and (68)Ga (67,8 min, 836 keV). (68)Ga was the only one not produced by cyclotron. Radiopharmaceuticals uptake by glucose metabolism ((18)F-FDG), lipogenesis ((11)C-Choline and (11)C-Acetate), amino acid transport (Anti-(18)F-FACBC), bone matrix ((18)F-NaF), prostatespecific membrane antigen ((68)Ga-PSMA and (89)Zr-J591), CXCR receptors ((89)Ga-Pentixafor), adrenal receptors ((18)F-FDHT) and gastrin release peptide receptor (bombesin analogue). Most of radiopharmaceuticals are urinary excretion, so bladder is the critical organ. 11C-choline (pancreas), Anti-(18)FFACBC (liver) and (18)F-FBDC (stomach wall) are the exception. Higher effective dose was seen (18)F-NaF (27 μSv/MBq) while the lowest was (11)CAcetate (3,5 μSv/MBq).

 

(후략)